FindTrial
Sign In

Analysis of the efficacy and safety of the initial empirical use of omadine combined with ß-lactamase inhibitors in the treatment of severe community-acquired bacterial pneumonia in adults

Analysis of the efficacy and safety of the initial empirical use of omadine combined with ß-lactamase inhibitors in the treatment of severe community-acquired bacterial pneumonia in adults

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125688
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-05-31
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe community-acquired bacterial pneumonia in adults

Interventions

ß-lactamase inhibitor + omacycline (BLI-OM) group:None
ß-lactamase inhibitor + moxifloxacin (BLI-MOX) group:None

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Community-acquired pneumonia; 2. Severe pneumonia; 3. Age >=18 years old; 4. Receive an initial empirical BLI-OM or BLI-MOX combination regimen for at least 3 days; 5. For patients with multiple hospitalizations, only data from the first hospitalization were used.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Transferred to other hospitals or departments; 3. Aspiration pneumonia; 4. The presence of 2019-nCoV infection; 5. Simple fungal, viral or atypical pathogen infections; 6. Tuberculosis; 7. Combined with malignant tumors and hematological diseases; 8. Acute cardio-cerebrovascular diseases.

Design outcomes

Secondary

MeasureTime frame
Markers of inflammation;—

Countries

China

Contacts

Public ContactWeichao Ding

The Affiliated Hospital of Xuzhou Medical University

dingweichao89@foxmail.com+86 516 8580 2162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026